<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2856B134-C51C-4260-A8A7-FB687E6C76D8"><gtr:id>2856B134-C51C-4260-A8A7-FB687E6C76D8</gtr:id><gtr:name>Indiana University</gtr:name><gtr:address><gtr:line1>Indiana University</gtr:line1><gtr:line2>PO Box 1847</gtr:line2><gtr:line4>Bloomington</gtr:line4><gtr:line5>IN 47404</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/41B65091-E579-4AAE-961D-1F9E1FE0DCB3"><gtr:id>41B65091-E579-4AAE-961D-1F9E1FE0DCB3</gtr:id><gtr:name>Remedi</gtr:name><gtr:address><gtr:line1>6, Lebuh Keluli</gtr:line1><gtr:line2>Kawasan Perindustrian Bukit Raja Selatan</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53043ABF-E596-42A9-B0A7-86CB0DD85DDF"><gtr:id>53043ABF-E596-42A9-B0A7-86CB0DD85DDF</gtr:id><gtr:name>Singapore Eye Research Institute</gtr:name><gtr:address><gtr:line1>SERI</gtr:line1><gtr:line2>11, Third Hospital Avenue 05.00</gtr:line2><gtr:line3>SNEC Building</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Centre for Vision &amp; Vascular Science</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2856B134-C51C-4260-A8A7-FB687E6C76D8"><gtr:id>2856B134-C51C-4260-A8A7-FB687E6C76D8</gtr:id><gtr:name>Indiana University</gtr:name><gtr:address><gtr:line1>Indiana University</gtr:line1><gtr:line2>PO Box 1847</gtr:line2><gtr:line4>Bloomington</gtr:line4><gtr:line5>IN 47404</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/41B65091-E579-4AAE-961D-1F9E1FE0DCB3"><gtr:id>41B65091-E579-4AAE-961D-1F9E1FE0DCB3</gtr:id><gtr:name>Remedi</gtr:name><gtr:address><gtr:line1>6, Lebuh Keluli</gtr:line1><gtr:line2>Kawasan Perindustrian Bukit Raja Selatan</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53043ABF-E596-42A9-B0A7-86CB0DD85DDF"><gtr:id>53043ABF-E596-42A9-B0A7-86CB0DD85DDF</gtr:id><gtr:name>Singapore Eye Research Institute</gtr:name><gtr:address><gtr:line1>SERI</gtr:line1><gtr:line2>11, Third Hospital Avenue 05.00</gtr:line2><gtr:line3>SNEC Building</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/915D733E-5C8C-4CE2-9036-0E787736F4C7"><gtr:id>915D733E-5C8C-4CE2-9036-0E787736F4C7</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Stitt</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7BB67107-AAEE-4AFD-ABBF-DB25C2DA79B5"><gtr:id>7BB67107-AAEE-4AFD-ABBF-DB25C2DA79B5</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Gardiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801962"><gtr:id>951DEE3A-5DAF-4851-BCC3-17BFEE8F82D4</gtr:id><gtr:title>CELL THERAPY FOR THE VASODEGENERATIVE STAGES OF DIABETIC RETINOPATHY</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801962</gtr:grantReference><gtr:abstractText>Diabetic Retinopathy is a leading cause of visual impairment. Even with current management regimens it continues to significantly reduce the quality of life for millions of affected individuals. Late stages of diabetic retinopathy can be treated or contained to some extent by pan-retinal laser photocoagulation but at the expense of causing damage to large areas of functional retina. Although a range of other therapeutic approaches are being developed, most are directed to end-stage retinopathy and fail to address the early pathology characterised by microvascular cell dysfunction and death. New treatments focusing on these early changes such as cell therapies to repair/replace abnormal diabetic vasculature are needed. This study will establish the baselines for the development of a novel ?stem cell? therapy based on induction of therapeutic angiogenesis by introducing highly defined populations of bone marrow-derived endothelial progenitor cells (EPCs) into the ischemic retina. 
 
Although EPCs have been shown to promote effective revascularisation of ischemic hearts in animal models, their definitive role in the ischemic retina remains unclear. This study will thoroughly assess any benefit obtained from injecting distinct EPCs into the vitreous of ischemic retinas.
Recently, it has been suggested that EPCs from type 1 diabetic patients are dysfunctional and display a reduced capacity to promote vascular repair. We plan to fully evaluate the function of EPC populations isolated from diabetic mice, and will test, for the first time, the possibility of healing diabetic dysfunctional progenitors by treating them with a statin.

EPCs are a highly heterogeneous group of cells. Depending on the subpopulation that is injected into the ischemic retina we anticipate promoting vascular repair by transplanting progenitors that become endothelial cells. Other EPC subpopulation transplants could actually exacerbate retinal damage by becoming inflammatory cells and this response this is important to determine. This study will clearly define the cell type with the capacity to promote vascular recovery and, importantly, will evaluate retinal function after cell therapy.
It is expected that endothelial progenitors from diabetic mice will be dysfunctional. We anticipate obtaining these cells from marrow, expanding them in the laboratory, correcting any inherent defect using statin treatment prior to ?transplanting? them into donor eyes. We expect that this approach will address the progressive retinal vascular damage that happens in diabetes and, ultimately, prevent vision loss.</gtr:abstractText><gtr:technicalSummary>Diabetes mellitus is increasing at an alarming rate and it has been estimated that by the year 2010 the total number of people with diabetes will reach 221 million worldwide. There are many complications of diabetes, but retinopathy remains the most common. Linked to the persistent fluctuations in blood glucose, dyslipidaemia and/or hypertension experienced by patients with diabetes, retinopathy constitutes a leading cause of blindness and visual impairment in the UK and the western world. 
Currently available treatments for diabetic retinopathy such as pan-retinal laser photocoagulation, vitreoretinal surgery, and recently introduced growth factor inhibitors are mainly focused on late, end-stages of the disease. Importantly, these therapies do not address the primary pathology of retinal neurovascular degeneration during diabetes that precedes pre-retinal neovascularisation and diabetic macular oedema. Fresh perspectives on the cellular and molecular mechanisms of diabetic retinopathy could lead to novel and much more effective prevention/reversal strategies. One such perspective is targeting the early and intermediate stages of vasodegeneration to enhance vessel repair and reverse ischaemia and prevent progression to the late, sight-threatening stages of diabetic retinopathy. For diabetic patients with an occluded retinal microvasculature, measures to preserve surviving vasculature and re-vascularise defunct capillary beds could extend the lifetime of the neuropile, reduce pathogenic output of vasoactive and neuropathic agents and ensure retention of serviceable vision.
The basis for the proposed novel therapeutic approach is to harness the vasoreparative potential of bone marrow-derived Endothelial Progenitors Cells (EPCs). These cells are recruited to sites of damage and promote vascular integrity in response to injury and/or reperfusion of ischaemic tissues. There is great discrepancy concerning the definition of EPCs but it is now widely accepted two distinct phenotypes exist. So-called, early EPCs (eEPCs) have low proliferative potential and monocytic features. They are recruited to sites of tissue damage where they promote vascular repair and angiogenesis in a paracrine manner by secreting many cytokines. There is little evidence for integration of eEPCs in pre-existing or neovasculature. The other cell-type, called Outgrowth Endothelial Cells (OECs), have high replicative potential and appear to incorporate directly into the vasculature, side by side with resident endothelial cells. Despite their potential, nothing is known about OECs interact with the specialised retinal microvasculature. It is important to establish the biological roles of OECs and eEPCs, determine how their response to the diabetic milieu and, importantly, their therapeutic utility for preventing or maybe even reversing diabetic retinopathy.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-21</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>499937</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Circulating Angiogenic Cells</gtr:description><gtr:id>05289D7A-4FF5-4435-98D8-6CF97579D278</gtr:id><gtr:impact>US-Ireland NIH application (submitted 2014)</gtr:impact><gtr:outcomeId>5464609a603bb1.73964092-1</gtr:outcomeId><gtr:partnerContribution>Providing cell isolation and characterisation skills</gtr:partnerContribution><gtr:piContribution>Shared working on CAC cells (sharing protocols, data, expertise)</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Remedi</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>REDDSTAR</gtr:description><gtr:id>D39EB30B-AB69-4225-B0BC-BA990BD423CC</gtr:id><gtr:impact>No outputs so far</gtr:impact><gtr:outcomeId>GsksEDNbJQj-1</gtr:outcomeId><gtr:partnerContribution>We are partners in the REDDSTAR grant based on harnessing the reparative function of stromal stem cells in diabetic vascular complications</gtr:partnerContribution><gtr:piContribution>EU-FP7 network involving multiple European partners</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Use of iPS cell technology to provide pericyte progenitors for diabetic retinopathy</gtr:description><gtr:id>59B88527-5BA3-4895-99D4-0306C1A51787</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>Z4qDqfMwrN2-1</gtr:outcomeId><gtr:partnerContribution>Sharing of knowledge and resources</gtr:partnerContribution><gtr:piContribution>Sharing of knowledge and resources.
Joint grant to a charity. Visits between groups</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Singapore Eye Research Institute</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>SERI (Singapore) collaboration</gtr:description><gtr:id>89C94AC2-1A10-48B0-8547-04E5F89A8A05</gtr:id><gtr:impact>Nothing yet</gtr:impact><gtr:outcomeId>HdYgQsBXFNC-1</gtr:outcomeId><gtr:partnerContribution>They will provide use of primate models</gtr:partnerContribution><gtr:piContribution>We are working together on animal models of vein occlusion.
We are providing expertise on the model and delivery of stem cells.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Indiana University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>iPS-derived EPCs</gtr:description><gtr:id>30D2B471-C380-40DF-BE44-41D084305B44</gtr:id><gtr:impact>Prasain N, Lee MR, Vemula S, Meador JL, Yoshimoto M, Ferkowicz MJ, Fett A, Gupta M, Rapp BM, Saadatzadeh MR, Ginsberg M, Elemento O, Lee Y, Voytik-Harbin SL, Chung HM, Hong KS, Reid E, O'Neill CL, Medina RJ, Stitt AW, Murphy MP, Rafii S, Broxmeyer HE, Yoder MC.
Nat Biotechnol. 2014 Nov;32(11):1151-7.</gtr:impact><gtr:outcomeId>54645ff28e4f38.22242590-1</gtr:outcomeId><gtr:partnerContribution>Joint working, shared expertise, joint publication</gtr:partnerContribution><gtr:piContribution>Development of iPS-based technologies and use of iPS-derived ECFCs (EPC) to reverse ischaemia in retina</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Sharing of reagents/resources</gtr:description><gtr:id>8B685244-65EE-45A5-9713-FE93E08C5023</gtr:id><gtr:impact>FASEB J. 2010 Dec;24(12):4816-24.</gtr:impact><gtr:outcomeId>WaKk5mR7Sqj-1</gtr:outcomeId><gtr:partnerContribution>Sharing of AGE moieties for our research</gtr:partnerContribution><gtr:piContribution>The collaboration was based on chemical synthesis expertise from the Case Western Partner (Prof Vicent Monnier)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>JDRF Charity information day, Belfast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>2B10B9B3-E317-4189-8967-72F9860C5866</gtr:id><gtr:impact>The Juvenile Diabetes Research Foundation organised a patient and supporters information day and I was asked to present my research on diabetic retinopathy.
There was considerable interest and discussion after the formal presentation and for periods afterwards.

Several patients have visited our unit to meet the researchers.</gtr:impact><gtr:outcomeId>cST2qwHVwRT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article for lay magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>B64F9E4F-0B57-42E4-A32F-3D847896B80C</gtr:id><gtr:impact>I wrote a &amp;quot;lay article&amp;quot; on diabetic retinopathy - new appraoches and upcoming therapies.

Several follow-up emails from interested readers</gtr:impact><gtr:outcomeId>iun7NWLm5Tx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CEC9F639-7948-423F-823C-6AB9952A8B51</gtr:id><gtr:impact>The talk was presented to patients and fund-raisers for ophthalmic research. They were given the opportunity learn about basic research ongoing in our laboraotry and the potential for transaltion into patient care.

Those attending were excited by the possibilities and interested to know how science is conducted</gtr:impact><gtr:outcomeId>Gifz84LuN7J</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>159000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Endothelial progenitor cell therapy for ischaemic retinopathy</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>C21D491E-9A18-4CD4-8498-C58933408F80</gtr:id><gtr:outcomeId>LQ5FATwwmoz0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A Translational Vision Science Building</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>81AEEA51-F61F-4FEC-8ADD-B45AC57A4436</gtr:id><gtr:outcomeId>iaXLQKALUMq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>169196</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of a novel approach for regenerating pericytes during diabetic retinopathy</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>4C0F72D4-495B-4960-A15C-B5E181CCE614</gtr:id><gtr:outcomeId>PZo64gW3C3R</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Harnessing the tissue-protective potential of erythropoietin (EPO) to prevent diabetic retinopathy</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>96D07D77-32C3-428D-9CD1-B08E70693C31</gtr:id><gtr:outcomeId>pCpVpdCKABn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Analysis of the vasoreparative and anti-inflammatory potential of a myelomonocytic endothelial progenitor cell (EPC) sub-type for treating diabetic retinopathy</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>1469E5D8-3C07-46BE-91CC-F42949DC311D</gtr:id><gtr:outcomeId>AdCPFo4VCdo0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>760000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Repair of Diabetic Damage by Stromal Cell Administration</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>11D73079-83C7-4AD3-9BC2-8425FAD99F7C</gtr:id><gtr:outcomeId>NpMkzUgxeMr</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cell therapy for ischaemic retinopathies</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Sir Jules Thorn Charitable Trust</gtr:fundingOrg><gtr:id>8707DDA1-C13E-4159-8847-29F85FA08A65</gtr:id><gtr:outcomeId>Zx3pn71sFvh0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>162196</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CAMKII: A Novel Therapeutic Target for Pathological Ocular Angiogenesis</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>D99CE28E-D205-4A10-9ADA-4618CCB58DB2</gtr:id><gtr:outcomeId>SasDc5E4Wt2</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>180519B7-214D-40E5-A2BC-12564E17ACE9</gtr:id><gtr:title>Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5ce43440634fc7d3a658fffdb18a1e6"><gtr:id>b5ce43440634fc7d3a658fffdb18a1e6</gtr:id><gtr:otherNames>Reid E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>5a96781b3c29b0.69244800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE6FA86C-58F6-4BB1-8AA1-1B52D19BAE4F</gtr:id><gtr:title>RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6738ffe8504874637d8ff442bad8580"><gtr:id>b6738ffe8504874637d8ff442bad8580</gtr:id><gtr:otherNames>Chen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>541b0296853b64.26099611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7633390-D4FC-4957-B2F9-11BE14DC1AE0</gtr:id><gtr:title>Endothelial progenitor cells in diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Frontiers in endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e37b36f08b2fb299a6b9bfc3dc12ee"><gtr:id>68e37b36f08b2fb299a6b9bfc3dc12ee</gtr:id><gtr:otherNames>Lois N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-2392</gtr:issn><gtr:outcomeId>541b0296b5a230.83458836</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FBDBAD6-EEE0-492E-944C-43570FE6959F</gtr:id><gtr:title>The role of immune-related myeloid cells in angiogenesis.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0cea2c3a8457e4f6ef52b1c44c8f5fe"><gtr:id>c0cea2c3a8457e4f6ef52b1c44c8f5fe</gtr:id><gtr:otherNames>Chambers SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>doi_14194_013_06_010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6D9716D-0C15-42EE-9EF4-DC820D1E4759</gtr:id><gtr:title>Differentiation of human pluripotent stem cells to cells similar to cord-blood endothelial colony-forming cells.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46f4955bf17ef875008df2e9d06a14cf"><gtr:id>46f4955bf17ef875008df2e9d06a14cf</gtr:id><gtr:otherNames>Prasain N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>54645d3f29a116.73355367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D5231EB-5A15-41F5-A45A-410452B61FDD</gtr:id><gtr:title>Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3f5480698124c69a107095775c88178"><gtr:id>f3f5480698124c69a107095775c88178</gtr:id><gtr:otherNames>Jarajapu YP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_14194_24_23230080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88306D21-D0BB-4843-A154-1B1D58ED17EE</gtr:id><gtr:title>Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>s9tudVoYVh9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CB166A6-9619-44D7-9023-7A229898C222</gtr:id><gtr:title>Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>YoASCgSqTQa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D576B4D-4A59-40D3-89DF-E3913A701199</gtr:id><gtr:title>Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40b536ff9db55f44233270363660b3ad"><gtr:id>40b536ff9db55f44233270363660b3ad</gtr:id><gtr:otherNames>Cahoon JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>56d44d1249c994.06656931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD63332D-F44B-43F9-BCA9-1EFC73B3C607</gtr:id><gtr:title>Endothelial progenitors as tools to study vascular disease.</gtr:title><gtr:parentPublicationTitle>Stem cells international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>L9iVeK54hFh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654E19A9-EB26-44F7-AF71-4D0F99B6FCB5</gtr:id><gtr:title>Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications.</gtr:title><gtr:parentPublicationTitle>Journal of diabetes research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c458ef9da6c87445aa74a3407e2e77"><gtr:id>74c458ef9da6c87445aa74a3407e2e77</gtr:id><gtr:otherNames>Rajasekar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d44d12ad8457.36301398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BD6B9E2-29FC-4963-B2F8-99B17F473A4A</gtr:id><gtr:title>Bone marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Progress in retinal and eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ff870f062bc8a2ebe63d033b02e9e4c"><gtr:id>5ff870f062bc8a2ebe63d033b02e9e4c</gtr:id><gtr:otherNames>Yellowlees Douglas J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9462</gtr:issn><gtr:outcomeId>pm_14194_24_22609081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07298AB4-C74E-4A4B-9B52-5DADEEEB181F</gtr:id><gtr:title>Vascular stem cells and ischaemic retinopathies.</gtr:title><gtr:parentPublicationTitle>Progress in retinal and eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ea3d2e7d3b8dbd663c71414cfa5675"><gtr:id>02ea3d2e7d3b8dbd663c71414cfa5675</gtr:id><gtr:otherNames>Stitt AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-9462</gtr:issn><gtr:outcomeId>SNmTYweQ4Na</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A1A26DF-A0A0-4944-9DC7-420D04C22178</gtr:id><gtr:title>Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5586effef9617de8367ebf7aba8970"><gtr:id>3e5586effef9617de8367ebf7aba8970</gtr:id><gtr:otherNames>McVicar CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>ZB3CmkM1vNV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5944B246-EB11-433C-92DF-8F9C91B9F3B2</gtr:id><gtr:title>MicroRNA-199b Modulates Vascular Cell Fate During iPS Cell Differentiation by Targeting the Notch Ligand Jagged1 and Enhancing VEGF Signaling.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2ecee2b070507a112d155f5463c6374"><gtr:id>a2ecee2b070507a112d155f5463c6374</gtr:id><gtr:otherNames>Chen T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>56d44d13189ce9.59987359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87D77BB1-881E-4D2F-B50B-0AE3208BDED4</gtr:id><gtr:title>Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab94a9d7718a3748f3459578960b9a37"><gtr:id>ab94a9d7718a3748f3459578960b9a37</gtr:id><gtr:otherNames>O'Neill CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>pm_14194_24_22897941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7246CDD6-DD97-443A-A10D-1BE3B11EE7B4</gtr:id><gtr:title>Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab607adf55a93d7e61bbd136b7179361"><gtr:id>ab607adf55a93d7e61bbd136b7179361</gtr:id><gtr:otherNames>Murugeswari P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54645d3f53ced1.08465587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF14FDFC-FDCE-4B29-BE26-B2AD23BD57A1</gtr:id><gtr:title>Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1bf9b6d654d6555b84b41e810398a3c"><gtr:id>d1bf9b6d654d6555b84b41e810398a3c</gtr:id><gtr:otherNames>Reynolds AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56d44d11a6af19.30246354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF6DE8EA-11C3-41D0-AAB2-42EEE34CD01A</gtr:id><gtr:title>Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.</gtr:title><gtr:parentPublicationTitle>Cardiovascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab94a9d7718a3748f3459578960b9a37"><gtr:id>ab94a9d7718a3748f3459578960b9a37</gtr:id><gtr:otherNames>O'Neill CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0008-6363</gtr:issn><gtr:outcomeId>58d3d727d3b4c6.25415704</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C988855A-F968-4632-9A0D-B7A3453434BD</gtr:id><gtr:title>Hypoxia-induced responses by endothelial colony-forming cells are modulated by placental growth factor.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7aa93fa317c471650fc3cb2b004401"><gtr:id>2d7aa93fa317c471650fc3cb2b004401</gtr:id><gtr:otherNames>Hookham MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>58d3d727801938.72996166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BB1E189-C202-453F-9B3F-5E0FB84007F9</gtr:id><gtr:title>Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0747403ba22c840eaaee8d68156e0183"><gtr:id>0747403ba22c840eaaee8d68156e0183</gtr:id><gtr:otherNames>Duh EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5a96781b64e367.48518806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBA17B31-83C5-4674-B717-C23695BD2053</gtr:id><gtr:title>Inhibition or deletion of 11?-HSD1 does not increase angiogenesis in ischemic retinopathy.</gtr:title><gtr:parentPublicationTitle>Diabetes &amp; metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce7133f8bdffb35f3410bade94262f7c"><gtr:id>ce7133f8bdffb35f3410bade94262f7c</gtr:id><gtr:otherNames>Davidson CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1262-3636</gtr:issn><gtr:outcomeId>58d3d7273ab439.18507133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25D4724D-F46E-40D7-91CB-9842EBA327B0</gtr:id><gtr:title>Ex vivo expansion of human outgrowth endothelial cells leads to IL-8-mediated replicative senescence and impaired vasoreparative function.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>pm_14194_24_23629812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18EF6AFD-7DEA-4890-ACAA-F897E26FDCDD</gtr:id><gtr:title>Endothelial Progenitors: A Consensus Statement on Nomenclature.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>58d3d72673b8b7.06845218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06630631-AF55-4264-8918-0897570C72A1</gtr:id><gtr:title>Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>Uru1mSB84rC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>316C4D38-1F76-40AE-8778-F59812C41436</gtr:id><gtr:title>Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ce4d73e652be683a7f5e29a0338e42"><gtr:id>28ce4d73e652be683a7f5e29a0338e42</gtr:id><gtr:otherNames>Medina RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>ZiD6VwbDiRx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51E99D7-2578-4218-98C0-16013F39631C</gtr:id><gtr:title>Quaking Is a Key Regulator of Endothelial Cell Differentiation, Neovascularization, and Angiogenesis.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bfa0c39973b7e32764306408d441df"><gtr:id>61bfa0c39973b7e32764306408d441df</gtr:id><gtr:otherNames>Cochrane A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>58d3d726e829c2.27685196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A9AB2B4-A149-44B5-8F4B-1C6E68093A57</gtr:id><gtr:title>The progress in understanding and treatment of diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Progress in retinal and eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ea3d2e7d3b8dbd663c71414cfa5675"><gtr:id>02ea3d2e7d3b8dbd663c71414cfa5675</gtr:id><gtr:otherNames>Stitt AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-9462</gtr:issn><gtr:outcomeId>56d44d1277b0c0.51807422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>225C077B-BFF1-4AFD-BD80-17471F17DF3C</gtr:id><gtr:title>Advances in our understanding of diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ea3d2e7d3b8dbd663c71414cfa5675"><gtr:id>02ea3d2e7d3b8dbd663c71414cfa5675</gtr:id><gtr:otherNames>Stitt AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>pm_14194_24_23485060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38FAFD22-08C8-445D-863E-759CC4E0201A</gtr:id><gtr:title>Advanced glycation end products and diabetic retinopathy.</gtr:title><gtr:parentPublicationTitle>Amino acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ca610f8d9b7eaab074c7f69ca304838"><gtr:id>0ca610f8d9b7eaab074c7f69ca304838</gtr:id><gtr:otherNames>Milne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0939-4451</gtr:issn><gtr:outcomeId>541b034a4cf251.09573297</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801962</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>